Enable AccessibilityEnable Accessibility

Shire to participate at the Leerink Partners 4th Annual Rare Disease Roundtable

September 29, 2015

Lexington, MA, USA – September 29, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Phil Vickers, Head of Research and Development and Jeff Poulton, Chief Financial Officer, will participate in the Leerink Partners 4th Annual Rare Disease Roundtable in New York City, NY on Wednesday, September 30, 2015, at 8:25 a.m. EDT (1:25 p.m. BST).

A live audio webcast will be available on the Presentations and Webcasts section of Shire's Investor website at http://investors.shire.com/presentations-and-webcasts/year-2015.aspx. Subsequently, a replay of the webcast will be available on this same website for approximately 90 days.

For further information please contact:

Investor Relations    
Matt Osborne [email protected] +1 781-482-9502
Sarah Elton-Farr [email protected] +44 1256 894157


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.